Is this cure claim worth your money?

Five plain things. Who was studied. What the treatment was compared with. How the change was measured. Who paid for the work. And whether the study was registered before it began.

Registered studies are listed in public. I checked ClinicalTrials.gov, a US government database. Sponsors submit the records, and a record can carry status, eligibility, locations and contacts. A US product also moves through set stages. Discovery comes first, then preclinical research, then clinical research, then FDA review, then post-market monitoring. Who was studied matters too. I read the FDA guidance that asks sponsors to plan enrollment for groups long left out of studies, and to write those goals down. How change was measured has set answers in psoriasis. The Psoriasis Area and Severity Index comes out as one number. The Dermatology Life Quality Index totals ten questions about your past week. I go through both in full on measuring change and on how severe is yours.

A listing is not approval. It is not proof of benefit, and it does not say whether you qualify. The FDA page on approvals is an overview of the stages, not a verdict on any product. The enrollment guidance is draft and nonbinding, and it describes no particular psoriasis study. If a pitch cannot answer these five questions, that is the finding. It is a reason to slow down, not a verdict on the product.

Compare the time, follow-up, daily effort, and practical burden of this exact path.

Confirm current availability, qualified support, coverage, and personal cost before relying on this path.

Ask what can be stopped or revisited and which outcomes remain uncertain.

Because psoriasis moves on its own. It can quiet down and come back with nothing to do with what you bought. So a person can be honest about what happened and wrong about the cause.

Psoriasis is an immune-mediated disease, and it is long term. There is no cure. An overactive immune system speeds up skin-cell growth. Cells that normally take about a month take three or four days instead. Flares have reported triggers. I read the American Academy of Dermatology list, which names stress, skin injury, infection, starting certain medicines, and cold dry weather. A flare after a skin injury usually shows about 10 to 14 days later. A flare after an infection such as strep throat is reported 2 to 6 weeks later. NIAMS records that handling common triggers, such as stress and skin injuries, can help keep symptoms under control. So a trigger that passes can be followed by calmer skin, whatever the person was taking that month.

None of these sources says whether one person will clear, stay the same or flare. NPF gives no share of people who reach a quiet spell, and no length for one. The AAD list cites no study for its timing windows, and counts nobody. Avoiding a listed trigger is not shown to stop a flare for any one person. A single story has nothing to compare itself with. That is why it cannot separate the product from the disease. I set out what is known about the pattern on will it clear or flare.

Compare the time, follow-up, daily effort, and practical burden of this exact path.

Confirm current availability, qualified support, coverage, and personal cost before relying on this path.

Ask what can be stopped or revisited and which outcomes remain uncertain.

No. Prescribed narrowband UVB is a medical device used under a dermatologist. A tanning bed is sold as a cosmetic service, and a salon sets nothing about your skin.

I checked how the FDA classifies ultraviolet lamps for skin disorders: Class II medical devices. Narrowband UVB slows the growth of fast-growing skin cells and calms an overactive immune system. It also reduces inflammation and reduces or removes itch. I read the AAD, which records that a dermatologist sets the plan and adjusts it. It also records real costs. Immediate ones include a sunburn-like reaction, mild stinging or burning, dark spots more common in medium-to-dark skin tones, itching, and rare blisters or burns. Longer-term ones include freckles, early skin aging and raised skin cancer risk. NPF records redness, stinging and burns, and asks for regular check-ups under medical supervision. I carry the full picture on the psoriasis narrowband UVB page.

None of these sources compares a tanning device with prescribed narrowband UVB. None of them measures what a salon session does to psoriasis. The FDA record describes a device category, and validates no single unit. Neither patient page gives a success percentage or a rate for any one side effect. If cost, travel or scheduling is what makes prescribed treatment hard, that barrier is the thing to raise at your next visit.

Compare the time, follow-up, daily effort, and practical burden of this exact path.

Confirm current availability, qualified support, coverage, and personal cost before relying on this path.

Ask what can be stopped or revisited and which outcomes remain uncertain.

People I have heard from ask whether a supplement or a diet cure is worth the money. No diet cures psoriatic disease. Eating patterns may lessen symptoms for some people, and that is a much smaller claim than a cure.

I read the National Psoriasis Foundation, which says plainly that no diet cures psoriatic disease. It reports that omega-3 supplement research is mixed and needs more long-term controlled studies. It reports that vitamin D research is small and limited, and that too much vitamin D can be dangerous. It reports that no study has found glucosamine or chondroitin reduce psoriatic arthritis symptoms. It says supplements should never replace medication, and to talk with your provider before changing how you eat. It advises a gluten-free diet only for confirmed gluten sensitivity or celiac disease. I checked NCCIH, which adds that supplement evidence and product content vary, and that interactions and contamination are possible. AAD links limiting alcohol to treatment working better and lasting longer. I carry the detail on the psoriasis diet page.

None of these sources says how much any food pattern or supplement changes symptoms for one person. NCCIH is not psoriasis evidence, and it checks no product for quality. The AAD page gives no percentage and no timeline for one person. A claim that a diet clears psoriasis for everyone goes past all three. So does a broad gluten claim, which NPF ties to a confirmed diagnosis.

Compare the time, follow-up, daily effort, and practical burden of this exact path.

Confirm current availability, qualified support, coverage, and personal cost before relying on this path.

Ask what can be stopped or revisited and which outcomes remain uncertain.

If a product will not say what is in it, nobody can judge it, including your dermatologist. A cream is not safer for being called natural. It is only unread.

I read NCCIH, which records that product content varies and that contamination is possible. I checked the FDA page on compounding. It records that compounded drugs are not FDA-approved, and that the agency does not check their safety, effectiveness or quality before they are marketed. Here is why the ingredient list matters. Topical steroids are real medicine with recorded effects. They run from least potent to super-potent. Reported side effects include skin thinning, pigment change, easy bruising, stretch marks, redness and dilated blood vessels. Absorption into the body is a risk with widespread, prolonged or covered use. Stopping one abruptly can set off a flare. AAD records that stronger products on thin skin such as the face carry skin-thinning, spider-vein and stretch-mark risk.

None of these sources tests a named over-the-counter cream. None of them says what any particular unlabeled product holds, or how often a mislabeled one turns up. The general rule stands without them. What cannot be read cannot be assessed. So take the actual jar or tube to your appointment, with the full ingredient list, rather than trying it alone. NPF already asks you to bring a record of your symptoms and share it. A product you are weighing belongs in the same bag.

Compare the time, follow-up, daily effort, and practical burden of this exact path.

Confirm current availability, qualified support, coverage, and personal cost before relying on this path.

Ask what can be stopped or revisited and which outcomes remain uncertain.